140 related articles for article (PubMed ID: 31566408)
21. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Kelley RK
J Clin Oncol; 2013 Oct; 31(28):3483-6. PubMed ID: 23980088
[No Abstract] [Full Text] [Related]
22. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
23. [Targeted HCC therapies: the door has been opened!].
Rosmorduc O; Fartoux L
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969
[No Abstract] [Full Text] [Related]
24. Systemic therapy for hepatocellular carcinoma.
Leung TW; Johnson PJ
Semin Oncol; 2001 Oct; 28(5):514-20. PubMed ID: 11685744
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
26. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
27. Medical treatment of hepatocellular carcinoma.
Luporini G; Labianca R; Pancera G
J Surg Oncol Suppl; 1993; 3():115-8. PubMed ID: 8389156
[No Abstract] [Full Text] [Related]
28. Immune oncology in hepatocellular carcinoma-hype and hope.
Wörns MA; Galle PR
Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
[No Abstract] [Full Text] [Related]
29. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Frenette CT; Frederick RT; Gish RG
J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of advanced hepatocellular carcinoma].
Forner A; Rodríguez De Lope C; Reig M; Bruix J
Gastroenterol Hepatol; 2010; 33(6):461-8. PubMed ID: 20227796
[TBL] [Abstract][Full Text] [Related]
32. [Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Fehér J; Lengyel G
Orv Hetil; 2010 Jun; 151(23):933-40. PubMed ID: 20494888
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitors to treat liver cancer.
Huynh H
Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
[TBL] [Abstract][Full Text] [Related]
34. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
Boland P; Wu J
Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
[TBL] [Abstract][Full Text] [Related]
35. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
36. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature.
Futsukaichi Y; Tajiri K; Kobayashi S; Nagata K; Yasumura S; Takahara T; Minemura M; Yasuda I
Clin J Gastroenterol; 2019 Apr; 12(2):128-134. PubMed ID: 30374884
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
38. Pfizer to make palbociclib temporarily free on NHS.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
[No Abstract] [Full Text] [Related]
39. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
40. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
Poon D; Anderson BO; Chen LT; Tanaka K; Lau WY; Van Cutsem E; Singh H; Chow WC; Ooi LL; Chow P; Khin MW; Koo WH;
Lancet Oncol; 2009 Nov; 10(11):1111-8. PubMed ID: 19880065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
